Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America
Cencora (NYSE: COR) has announced a definitive agreement to acquire Retina Consultants of America (RCA) from Webster Equity Partners for $4.6 billion in cash. RCA is a leading management services organization of retina specialists, with nearly 300 specialists across 23 states conducting over 2 million patient visits annually. Cencora will hold approximately 85% ownership, while RCA's affiliated practices, physicians, and management will retain a minority interest. The acquisition is expected to be $0.35 accretive to Cencora's adjusted diluted EPS in its first twelve months and includes potential contingent payments up to $500 million in fiscal years 2027 and 2028.
Cencora (NYSE: COR) ha annunciato un accordo definitivo per acquisire Retina Consultants of America (RCA) da Webster Equity Partners per un importo di 4,6 miliardi di dollari in contante. RCA è una delle principali organizzazioni di servizi di gestione specializzate nella retina, con quasi 300 specialisti distribuiti in 23 stati che effettuano oltre 2 milioni di visite annuali. Cencora deterrà circa l'85% della proprietà, mentre le pratiche, i medici e la gestione affiliate a RCA manterranno una partecipazione minoritaria. Si prevede che l'acquisizione avrà un effetto positivo di $0,35 sull'EPS diluito rettificato di Cencora nei primi dodici mesi e include pagamenti contingenti potenziali fino a 500 milioni di dollari negli anni fiscali 2027 e 2028.
Cencora (NYSE: COR) ha anunciado un acuerdo definitivo para adquirir Retina Consultants of America (RCA) de Webster Equity Partners por 4,6 mil millones de dólares en efectivo. RCA es una organización líder de servicios de gestión de especialistas en retina, con casi 300 especialistas en 23 estados que realizan más de 2 millones de visitas de pacientes al año. Cencora poseerá aproximadamente el 85% de la propiedad, mientras que las prácticas, médicos y la administración afiliados a RCA retendrán un interés minoritario. Se espera que la adquisición sea $0.35 aditiva al EPS diluido ajustado de Cencora en sus primeros doce meses e incluye posibles pagos contingentes de hasta $500 millones en los años fiscales 2027 y 2028.
센코라 (NYSE: COR)는 레티나 컨설턴트 오브 아메리카 (RCA)를 웹스터 에쿼티 파트너로부터 현금으로 46억 달러에 인수하기 위한 확정 계약을 발표했습니다. RCA는 거의 300명의 전문의를 보유한 주요 망막 전문 관리 서비스 조직으로, 23개 주에서 연간 200만 건 이상의 환자 방문을 진행합니다. 센코라는 약 85%의 지분을 보유하며, RCA의 제휴된 진료소, 의사 및 경영진은 소수 지분을 유지합니다. 이번 인수는 센코라의 조정된 희석 EPS에 대해 처음 12개월 동안 $0.35가 증가할 것으로 예상되며, 2027 및 2028 회계 연도에는 최대 $5억 달러의 잠재적 조건부 지급이 포함됩니다.
Cencora (NYSE: COR) a annoncé un accord définitif pour acquérir Retina Consultants of America (RCA) de Webster Equity Partners pour un montant de 4,6 milliards de dollars en espèces. RCA est une organisation de services de gestion de spécialistes de la rétine, comptant près de 300 spécialistes dans 23 États, réalisant plus de 2 millions de visites de patients par an. Cencora détiendra environ 85 % des parts, tandis que les pratiques, médecins et la direction affiliés à RCA conserveront un intérêt minoritaire. L'acquisition devrait augmenter le BPA dilué ajusté de Cencora de 0,35 $ au cours des douze premiers mois et inclut des paiements conditionnels potentiels pouvant atteindre 500 millions de dollars durant les exercices fiscaux 2027 et 2028.
Cencora (NYSE: COR) hat eine verbindliche Vereinbarung zur Übernahme von Retina Consultants of America (RCA) von Webster Equity Partners für 4,6 Milliarden Dollar in bar bekannt gegeben. RCA ist eine führende Managementdienstleistungsorganisation für Netzhautspezialisten mit fast 300 Spezialisten in 23 Bundesstaaten, die jährlich über 2 Millionen Patientenbesuche durchführen. Cencora wird etwa 85% der Anteile halten, während die angeschlossenen Praxen, Ärzte und das Management von RCA einen Minderheitsanteil behalten. Die Übernahme dürfte in den ersten zwölf Monaten einen akquisitorischen Effekt von $0,35 auf das angepasste verwässerte EPS von Cencora haben und umfasst mögliche bedingte Zahlungen von bis zu 500 Millionen Dollar in den Geschäftsjahren 2027 und 2028.
- Acquisition expected to be $0.35 accretive to EPS in first twelve months
- Expands specialty healthcare presence with 300 retina specialists across 23 states
- Adds 40 clinical trial sites and 400 dedicated research employees
- RCA conducts over 2 million patient visits annually
- Strategic expansion into high-growth retina care segment
- Significant cash outlay of $4.6 billion plus potential $500 million in contingent payments
- New debt financing required to fund the transaction
- Post-acquisition de-leveraging prioritization needed to maintain credit rating
Insights
This
- Expansion into specialty MSO services with RCA's network of 300 specialists across 23 states
- Enhanced clinical research capabilities through RCA's 40 trial sites
- Strengthened relationships with pharmaceutical manufacturers in the retina space
This acquisition strategically positions Cencora in the rapidly growing retina care market, which is experiencing increased demand due to aging demographics and rising prevalence of conditions like diabetic retinopathy and macular degeneration. RCA's 2 million annual patient visits demonstrate significant market penetration. The deal strengthens Cencora's competitive position by:
- Expanding its specialty care portfolio beyond oncology
- Creating synergies between pharmaceutical distribution and clinical services
- Building a stronger platform for specialty drug commercialization
“The acquisition of RCA will allow Cencora to broaden our relationships with community providers in a high growth segment and build on our leadership in specialty,” said Bob Mauch, President & CEO of Cencora. “With a compelling value proposition for physicians, an impressive leadership team and strong clinical research capabilities, RCA is well-positioned at the forefront of retinal care. We intend to use our leading operational infrastructure to help RCA enhance the provider experience, drive innovative new research and create better outcomes for patients. Following our recent investment in OneOncology, the addition of RCA will allow us to expand our MSO solutions and drive differentiated value across the healthcare system for manufacturers, providers and patients.”
“We are pleased to enter our next phase of growth with the support of a leading global pharmaceutical solutions organization,” said Robby Grabow, Chief Executive Officer of RCA. “With additional resources to support the continued execution of our growth strategy, we will be better positioned to continue expanding our physician network and enhancing the quality of care we provide.”
“The ability to become a part of Cencora and its purpose-driven culture, will further advance RCA’s mission of saving sight and improving the lives of our patients and communities we serve through innovation,” said David Brown, MD, Co-Chair of RCA’s Medical Leadership Board. “Our cultural alignment and shared focus on driving innovation will allow us to unlock new opportunities together and advance the caliber of retina care.”
The proposed transaction will build on Cencora’s key strategic imperatives and areas of focus by:
- Adding a leader in the community provider space to Cencora: RCA is the leading MSO in the retina space and a trusted healthcare provider. RCA’s nearly 300 retina specialists across 23 states provide high-quality care to patients with physicians conducting over 2 million visits annually.
- Expanding Cencora’s leadership in Specialty: As the specialty landscape continues to evolve, providers are increasingly seeking partners to assist with managing their practices while retaining their autonomy and patient-centric approach. The addition of RCA will add to Cencora’s capabilities in Specialty and expand its MSO business, broadening physician and manufacturer relationships as well as Cencora’s value proposition to all its stakeholders.
- Investing in innovation and contributing to Rx outcomes: RCA has an impressive clinical track record and operates a premier clinical research network with 40 clinical trial sites spanning Phases I-IV and 400 dedicated full-time research employees. Cencora expects to use its suite of manufacturer services to enhance RCA’s research program and outcomes, maintaining its position as a partner of choice to pharmaceutical innovators in the retina space.
Transaction Details
Cencora will acquire RCA for approximately
The transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals.
Upon closing, the acquisition of RCA is expected to be approximately
“Cencora is committed to maintaining its strong investment grade credit rating and will prioritize de-leveraging in the years following transaction close,” said Jim Cleary, EVP & Chief Financial Officer.
Advisors
Lazard is serving as exclusive financial advisor, and Freshfields LLP, Sidley Austin LLP and Morgan, Lewis & Bockius LLP are serving as legal advisors to Cencora. Goldman Sachs & Co. LLC and Rothschild & Co are serving as financial advisors, and Goodwin Procter LLP and ReedSmith LLP are serving as legal advisors to RCA.
About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. Cencora partners with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on Cencora for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Cencora’s 46,000+ worldwide team members contribute to positive health outcomes through the power of Cencora’s purpose: Cencora is united in its responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #24 on the Global Fortune 500 with more than
About Webster Equity Partners
Founded in 2003,
Cencora’s Cautionary Note Regarding Forward-Looking Statements
Certain of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”). Such forward-looking statements may include, without limitation, statements about the proposed transaction with RCA, the expected timetable for completing the proposed transaction, the benefits of the proposed transaction, future opportunities for Cencora and RCA and any other statements regarding Cencora’s or RCA’s future operations, financial or operating results, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, and other expectations for future periods. Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,”, “estimate,” "expect," “intend,” “may,” “might,” “on track,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “sustain,” “synergy,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the parties’ ability to meet expectations regarding the timing of the proposed transaction; the parties’ ability to consummate the proposed transaction; the regulatory approvals required for the proposed transaction not being obtained on the terms expected or on the anticipated schedule or at all; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with GAAP and related standards, or on an adjusted basis; Cencora’s or RCA’s failure to achieve expected or targeted future financial and operating performance and results; the possibility that Cencora may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the proposed transaction within the expected time frames or at all; business disruption being greater than expected following the proposed transaction; the recruiting and retention of key physicians and employees being more difficult following the proposed transaction; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of the business of Cencora or RCA; Cencora's de-leveraging plans and the ability of Cencora to maintain its investment grade rating; and uncertainties and matters beyond the control of management and other factors described under “Risk Factors” in Cencora’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC. You can access Cencora’s filings with the SEC through the SEC website at www.sec.gov or through Cencora’s website, and Cencora strongly encourages you to do so. Except as required by applicable law, Cencora undertakes no obligation to update any statements herein for revisions or changes after the date of this communication.
This press release is neither an offer to sell nor a solicitation of an offer to buy any securities of Cencora. Any such offer will only be made pursuant to a prospectus filed with the SEC or pursuant to one or more exemptions from the registration requirements of the Securities Act of 1933, as amended.
Supplemental Information Regarding Non-GAAP Financial Measure
To supplement the financial measures prepared in accordance with
The non-GAAP financial measure is presented because Cencora’s management uses non-GAAP financial measures to evaluate Cencora’s operating performance, to perform financial planning, and to determine incentive compensation. Therefore, Cencora believes that the presentation of the non-GAAP financial measure provides useful supplementary information to, and facilitates additional analysis by, investors. The presented non-GAAP financial measure excludes items that management does not believe reflect Cencora’s core operating performance because such items are outside the control of Cencora or are inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.
Cencora does not provide a reconciliation for this non-GAAP financial measure on a forward-looking basis to the most comparable GAAP financial measure on a forward-looking basis because it is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort due to the uncertainty and potential variability of reconciling items, which are dependent on future events, are out of Cencora’s control and/or cannot be reasonably predicted, and the probable significance of which cannot be determined.
This press release includes adjusted diluted earnings per share (“EPS”), which represents diluted earnings per share determined in accordance with GAAP adjusted for specific items, including the per share impact of: gains from antitrust litigation settlements;
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105587321/en/
Investors:
Bennett S. Murphy
610-727-3693
Bennett.Murphy@cencora.com
Media:
Lauren Esposito
215-460-6981
Lauren.Esposito@cencora.com
Source: Cencora
FAQ
How much is Cencora (COR) paying to acquire Retina Consultants of America?
What ownership percentage will Cencora (COR) have in RCA after the acquisition?
How will the RCA acquisition impact Cencora's (COR) earnings?